#AACR18 round 1: Merck takes a direct swing at Bristol-Myers with adjuvant melanoma data for Keytruda
CHICAGO — Merck $MRK came out of its corner swinging Sunday morning, taking a few direct jabs at the defending champion in checkpoint inhibition as the pharma giant entered the latest I/O title fight with Bristol-Myers Squibb $BMY at the annual meeting of AACR in Chicago.
Researchers for Merck were in Chicago for the curtain opener in what promises to be a bruising brawl between the leaders in the PD-1 field over a market one analyst has said is worth $3 billion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.